X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to co-develop Helicon-enabled 212Pb alpha radioligand therapies by leveraging FogPharma’s field-leading Helicon platform and ARTBIO’s AlphaDirect™ platform, for cancer.
Lead Product(s): 212Pb Alpha Radioligand Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: ARTBIO
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 14, 2024
Details:
The financing will fund the ongoing clinical development of FOG-001, the company’s first-in-class intracellular TCF-blocking β-catenin inhibitor for the treatment of locally advanced or metastatic solid tumors.
Lead Product(s): FOG-001
Therapeutic Area: Oncology Product Name: FOG-001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $145.0 million Upfront Cash: Undisclosed
Deal Type: Series E Financing March 01, 2024
Details:
FOG-001 first-in-class TCF-blocking β-catenin inhibitor proprietary and conformationally stabilized α-helical polypeptide (Helicon™) therapeutics, which being investigated for first-in-class TCF-blocking β-catenin inhibitor Advanced Solid Tumors.
Lead Product(s): FOG-001
Therapeutic Area: Oncology Product Name: FOG-001
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
Proceeds from the Series D financing will be used to advance and accelerate FogPharma’s growing pipeline of hyperstabilized α-helical (Helicon™) polypeptide therapeutics. FOG-001, a first-and-only-in-class direct TCF-blocking β-catenin inhibitor.
Lead Product(s): FOG-001
Therapeutic Area: Oncology Product Name: FOG-001
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: ARCH Venture
Deal Size: $178.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing November 21, 2022
Details:
FOG-001, a first-in-class direct TCF-blocking β-catenin inhibitor, pioneering Helicon modality, a new class of precision medicines that aim to combine the targeting strength and specificity of antibodies with the cell penetration of small molecules.
Lead Product(s): FOG-001
Therapeutic Area: Oncology Product Name: FOG-001
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
FogPhama’s proprietary Helicon™ peptides represent a new class of precision medicines that combines the targeting strength and specificity of antibodies with the cell penetration of small molecules.
Lead Product(s): Helicon peptides-based therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: venBio Partners
Deal Size: $107.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
